Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

NCT00842998 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab or Lapatinib

Sponsor

Azienda Ospedaliera Ordine Mauriziano di Torino